← All stocks

Stock news timeline · NOVARTIND

Novartis

News timeline · Last 30 days

23 Aug 2026 – 21 Sep 2026 · Times in IST

Timeline updates
14
Bullish
4
Neutral
7
Bearish
3
Active days
6

News timeline

Showing 14 of 14 updates · Newest first

Friday, 18 Sep 20261 update

AI sentiment: Neutral 91% confidence

Novartis India Updates AGM Notice, Clarifies ESOP 2026 Details

Novartis India issued a corrigendum for its 78th AGM Notice, clarifying ESOP 2026 details. Corrections include omitted disclosures on ESOP rules and industry classification as 'Pharmaceutical Industry'. Source: BSE

Friday, 11 Sep 20262 updates

AI sentiment: Neutral 89% confidence

Novartis India Unveils Strategy; ChrysCapital Takes 70.7% Stake

Novartis India Ltd hosted an investor call presenting its business strategy, governance framework, and M&A updates. Key updates include brand acquisitions, new management appointments, and ChrysCapital's 70.7% stake acquisition with plans for a name change. Source: BSE

AI sentiment: Neutral 90% confidence

Novartis India Details Strategy, M&A in Analyst Call

Novartis India held analyst call on Sep 11, 2026; presentation on website. Business strategy, M&A, vision discussed; no unpublished price-sensitive info. Source: ScoutQuest

Wednesday, 09 Sep 20261 update

AI sentiment: Bullish 91% confidence

Novartis India Surges 17%, Up 29% This Week

Novartis India surged nearly 17% today, marking significant growth. The stock has gained over 29% week-to-date, reflecting strong momentum. Source: ScoutQuest

Tuesday, 08 Sep 20265 updates

AI sentiment: Neutral 93% confidence

Novartis India: Will Meet Analysts And Investors On September 10 At 4 PM.

AI sentiment: Bearish 76% confidence

Pfizer Hits 52-Week Low, Falls 6%; Novartis India Surges 13%

Pfizer shares dropped 6%, hitting a 52-week low of Rs 4,320.4 after halting Minipress XL sales. Novartis India surged 13%, while Pfizer cited US decision to stop Minipress XL production. Source: Business Today

AI sentiment: Bearish 86% confidence

Novartis Stock Dips on 3rd Drug Trial Failure

Novartis faces its third drug trial failure in a week with del-desiran. The failure leads to a decline in Novartis' stock price. Source: ScoutQuest

AI sentiment: Bullish 76% confidence

Novartis India Signs ₹10 Cr Deal for Retinal Products

Novartis India inks exclusive deal with Novartis Healthcare for retinal products. Agreement includes INR 10 crore upfront, entering India's ophthalmology therapy area. Source: ScoutQuest

AI sentiment: Bullish 84% confidence

Novartis India: Co. Enters Exclusive Promotion And Distribution Agreement With NHPL For Retina Portfolio; Expands Commercial Portfolio In Ophthalmology.

Monday, 07 Sep 20264 updates

AI sentiment: Neutral 91% confidence

Karan Bhagat Buys 1.3L Novartis Shares at ₹1670.5 Each

Karan Bhagat purchased 130,000 shares of Novartis India at ₹1670.5/share. The total transaction value was ₹21.7 crore on 2026-09-07. Source: ScoutQuest

AI sentiment: Bearish 51% confidence

Novartis Heart Drug Fails Final Trial, Faces Hurdles

Novartis' heart drug failed in the final trial phase, posing challenges. Source: ScoutQuest

AI sentiment: Bullish 77% confidence

Novartis India: Gets Approval to Buy ‘Minipress’ and ‘Minipres’ Trademarks and Other Related Rights from Pfizer for ₹1250 Crore

AI sentiment: Neutral 83% confidence

Novartis to Buy Minipress Brand from Pfizer for ₹1,250 Cr

Novartis India to acquire Minipress/Minipres trademarks from Pfizer for INR 1,250 crore. Minipress XL revenue reported at INR 228.6 crore with 6.3% CAGR. Source: ScoutQuest

Wednesday, 02 Sep 20261 update

AI sentiment: Neutral 78% confidence

Novartis India Sets AGM for Sep 24; Eyes Growth via Acquisitions, Tier 2/3 Push

Novartis India Ltd announces its 78th AGM on Sep 24, 2026 via video conferencing, adhering to SEBI regulations. The company plans portfolio expansion, strategic acquisitions, and deeper Tier 2/3 market penetration to drive growth. Source: BSE